AdvanCell reports 80% PSA response with ADVC001 in updated Phase 1 prostate cancer study
AdvanCell reports an 80% PSA response and 11.2-month median rPFS with ADVC001. Small Phase 1 numbers leave important efficacy questions.
Pharma & Biotech
Pharma & Biotech
Merck and Moderna report 42% lower melanoma recurrence risk in Phase 3 mRNA trial
Merck and Moderna report 42% lower melanoma recurrence risk with intismeran plus Keytruda. Survival, safety and manufacturing remain key.
Pharma & Biotech
Aulos saw lung tumors shrink up to 48% in early testing. Can its IL-2 combination deliver more?
Aulos Bioscience will present Phase 2 findings for imneskibart, low-dose interleukin-2 and avelumab in checkpoint-resistant lung adenocarcinoma. Earlier findings showed tumor shrinkage in a small cohort, but the forthcoming ESMO data must establish response rates, durability and safety more clearly.
Pharma & Biotech
What will Insilico Medicine reveal about ISM6331 at the ESMO 2026 Congress?
Insilico Medicine’s first human data for ISM6331 will arrive as clinical interest in TEAD inhibition is accelerating. The presentation must show whether the AI-designed molecule can combine credible antitumor activity with a dose and safety profile suitable for further development.
Pharma & Biotech
Why Incyte’s ESMO 2026 oncology readouts matter for its expanding Phase 3 pipeline
Incyte’s ESMO 2026 programme puts three investigational cancer assets under scrutiny across pancreatic, colorectal and ovarian tumours.